National Cholesterol Education Panel III performance in preventing myocardial infarction in young adults

Jean G Dib, Yasmine Alameddine, Rouba Geitany, Fadi Afiouni, Jean G Dib, Yasmine Alameddine, Rouba Geitany, Fadi Afiouni

Abstract

Background: Only one published trial has directly evaluated the utility of the new National Cholesterol Education Program (NCEP) guidelines in young adults and that study population consisted of young Americans. We examined the utility of the latest NCEP Adult Treatment Panel III (ATP III) guidelines in a group of young Lebanese adults.

Methods: A group of 234 young adults admitted for myocardial infarction at a Lebanese teaching hospital over a 2-year period were evaluated retrospectively. The Framingham risk predictor model was used to calculate the 10-year risk for coronary events in all subjects.

Results: Two hundred young Lebanese adults with a mean age of 49.7+/-7.6 years were included in the analysis. The majority of the study population had a history of smoking (67%) and LDL cholesterol <130 mg/dL (70.5%) and were considered overweight and obese (80.5%). As a group, 80% did not meet the criteria to qualify for antilipemic pharmacotherapy prior to their presentation.

Conclusion: The predictive model did not detect the majority of these patients. Clinicians should treat modifiable risk factors with the same intensity given to cholesterol even if the patient has a normal lipid profile.

References

    1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85–151.
    1. GISSI Investigators. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction. Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto-1 study. Circulation. 1998;98:2659–65.
    1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–82.
    1. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001;357:1385–90.
    1. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J. 1988;9:8–16.
    1. Held PH, Yusuf S. Effect of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J. 1993;14(Suppl F):18–15.
    1. Beta-Blocker Heart Attack Study Group. The Beta-Blocker Heart Attack Trial. JAMA. 1981;246:2073–4.
    1. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998;97:2202–12.
    1. SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77.
    1. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infraction Ramipril Efficacy. Lancet. 1997;349:1493–7.
    1. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308:81–106.
    1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–60.
    1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet. 1996;348:1329–39.
    1. Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol. 2000;36:699–705.
    1. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.
    1. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes SGE. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(2):185–97.
    1. Cheung BM, Lauder IJ, Lau CP, Kumana RC. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57(5):640–51.
    1. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004;164(13):1427–36.
    1. Burr ML, Gilbert JF, Holiday RM, et al. Effects of changes in fat, fish and fiber intakes on death and myocardial reinfarction: diet and reinfarction trial (DART) Lancet. 1989;334:757–61.
    1. De Lorgeril M, Renaud S, Salen P, et al. Mediterranean alpha-linolenic acid-rich diet in the secondary prevention of coronary heart disease. Lancet. 1994;343:1454–9.
    1. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295(6):655–66.
    1. Stevens VJ, Glasgow RE, Toobert DJ, Karanja N, Smith S. Randomized trial of a brief dietary intervention to decrease consumption of fat and increase consumption of fruits and vegetables. Am J Health Promotion. 2002;16:129–34.
    1. Iestra JA, Kromhout D, Van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation. 2005;112(6):924–34.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001;285(19):2486–97.
    1. Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239.
    1. Akosah KO, Schaper A, Cogbill C, Cogbill C, Schoenfeld P. Preventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform? J Am Coll Cardiol. 2003;41:1475–9.
    1. NHLBI Obesity Education Initiative Expert Panel. Clinical Guidelines on Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1998. NIH publication no. 98-4083.
    1. Akosah K. Premature CAD and the new NCEP guidelines. Cardiol Rev. 2001;18:31–34.
    1. Fedder DO, Koro CE, L’Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid lowering drug therapy. Projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation. 2002;105:152–6.
    1. Akosah KO, Gower E, Groon L, Rooney LB, Schaper A. Mild hypercholesterolemia and premature heart disease: do the national criteria underestimate disease risk? J Am Coll Cardiol. 2000;35:1178–84.
    1. Mora S, Blumenthal RS. Identifying risk factors for premature CAD. Cardiol Rev. 2001;18:33–4.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa